Screening for IDH mutations in chronic myelomonocytic leukemia

Leukemia and Lymphoma

Volumn 54, Issue 2, 2013, Pages 406-407

  Ibañez, Mariam ^a   Such, Esperanza ^a   Cervera, José ^a   Luna, Irene ^a   Gómez Seguí, Inés ^a   López Pavía, María ^a   Avaria, Amparo ^a   Senent, M Leonor ^a   Sanz, Guillermo F ^a   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; HEMOGLOBIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2;

ALLELE; BONE MARROW CELL; CANCER PROGNOSIS; CANCER SCREENING; CHRONIC MYELOMONOCYTIC LEUKEMIA; CODON; EXON; GENE DUPLICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; LEUKOCYTE COUNT; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THROMBOCYTE COUNT; WILD TYPE;

EARLY DETECTION OF CANCER; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MUTATION;

EID: 84872021899     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.701295     Document Type: Letter

References (14)

1. Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010; 95: 1668-1674.
2. Ward PS, Patel J, Wise DR, et al. Thecommon feature of leukemiaassociated IDH1 and IDH2 mutations is aneomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
3. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010; 24: 1094-1096.
4. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25: 1200-1202.
5. Yoshida K, Sanada M, Kato M, et al. Anonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia 2011; 25: 184-186.
6. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118: 3932-3941.
7. Yamazaki J, Taby R, Vasanthakumar A, et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012; 7: 201-207.
8. Zhao S, Lin Y, Xu W, et al. Glioma derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
9. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
10. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. JExp Med 2010; 207: 339-344.
11. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. NEngl JMed 2010; 362: 369-370.
12. Wagner K, Damm F, G ö hring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. JClin Oncol 2010; 28: 2356-2364.
13. Lin J, Yao DM, Qian J, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2012; 91: 519-525.
14. Orazi A, Bennett JM, Germing U, et al. Chronic myelomonocytic leukaemia. In: Swerdlow S, Campos E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp. 76-81.